发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Cancer Drug Approvals in China Outpace Those in US, Study Finds China has strategically invested in its biopharmaceutical sector over the last decade to make it more competitive and a go-to partner for pharmaceutical companies around the world.
发布时间
81 天前
2026-07-20 15:00:00 UTC
源站更新
81 天前
2026-07-20 15:00:00 UTC
首次抓取
81 天前
2026-07-20 16:55:19 UTC
研究发现，2020 至 2025 年间，中国批准的新癌症药物数量超过美国，表明中国在生物科技产业投资上提升了全球竞争力，但在首创药物领域美国仍占主导。
A study finds China approved more novel cancer drugs than the US from 2020 to 2025, reflecting growing global competitiveness in its biotechnology sector, though the US still leads in first-in-class drug approvals.
用于追踪这条内容的来源与记录标识。
